GoodRx (NASDAQ:GDRX - Get Free Report) issued its earnings results on Thursday. The company reported $0.04 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.06), Zacks reports. The company had revenue of $198.58 million for the quarter, compared to the consensus estimate of $199.73 million. GoodRx had a positive return on equity of 5.35% and a negative net margin of 2.05%. GoodRx updated its FY 2025 guidance to EPS and its Q1 2025 guidance to EPS.
GoodRx Stock Down 2.6 %
Shares of GoodRx stock traded down $0.13 during trading on Monday, reaching $4.85. The stock had a trading volume of 2,507,767 shares, compared to its average volume of 1,343,864. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70. The company has a market capitalization of $1.85 billion, a price-to-earnings ratio of -161.67, a P/E/G ratio of 2.46 and a beta of 1.28. The stock has a fifty day moving average price of $4.71 and a two-hundred day moving average price of $5.73. GoodRx has a 52 week low of $4.09 and a 52 week high of $9.26.
Analysts Set New Price Targets
Several research analysts recently weighed in on GDRX shares. Wells Fargo & Company reduced their price objective on shares of GoodRx from $9.00 to $8.00 and set an "overweight" rating on the stock in a research note on Friday. Barclays reduced their price target on shares of GoodRx from $10.00 to $6.00 and set an "overweight" rating on the stock in a research report on Monday, November 11th. Mizuho started coverage on shares of GoodRx in a research report on Wednesday, December 4th. They issued a "neutral" rating and a $5.00 price objective for the company. Citigroup reduced their target price on GoodRx from $7.00 to $6.25 and set a "buy" rating on the stock in a report on Friday, January 10th. Finally, Morgan Stanley decreased their target price on GoodRx from $7.00 to $6.00 and set an "equal weight" rating for the company in a research note on Tuesday, December 17th. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, GoodRx presently has an average rating of "Moderate Buy" and an average target price of $8.18.
Read Our Latest Research Report on GDRX
GoodRx Company Profile
(
Get Free Report)
GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.
Featured Articles
Before you consider GoodRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GoodRx wasn't on the list.
While GoodRx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
